NCT02908672 2025-07-20A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced MelanomaHoffmann-La RochePhase 3 Completed514 enrolled 25 charts 2 FDA
NCT02788279 2019-12-11A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)Hoffmann-La RochePhase 3 Completed363 enrolled 19 charts
NCT02427893 2016-11-15Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant MelanomaSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 3 Withdrawn